Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A simple, repeatable way to completely remove a clot from the brain in one pass

Project description

Simplifying clot removal could improve outcomes for millions with ischaemic stroke

Stroke is a decrease or cessation of blood flow to a part of the brain, depriving it of essential oxygen and nutrients. Brain cells, unlike other cells in the body, begin to die within minutes. Eighty percent of strokes are ischaemic strokes that occur when arteries become narrowed or blocked by a clot. Several large and recent studies have shown that endovascular procedures to remove the clot might be the most effective treatment. Perfuze has developed easy-to-use technology to aspirate the clot via a catheter, removing it in a single attempt by a single skilled operator. The team is now taking the device to market to mitigate the huge global mortality and morbidity associated with ischaemic stroke.

Objective

Stroke is the third most common cause of death globally and is the leading cause of adult physical disability. Globally, seventeen million people had a stroke in 20152. Of these, 33% died and 33% were permanently disabled. A stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow, and causing brain damage. Stroke is a devastating disease.

Perfuze has developed aspiration catheter technology intended to ingest the clot in a single attempt. No accessory devices or sophisticated techniques are required, meaning the procedure can be performed by a single operator. This maximises the chance of complete clot ingestion within the occluded vessel, complete flow restoration and improved patient outcomes.

Multiple iterations have been required to reach the existing Millipede design. Pilot manufacturing lines utilising customised coiling and
wire forming equipment have been built. Component and assembly drawings and specifications have been defined. Six preclinical animal studies have been performed to compliment proof-of-concept bench testing.

The potential market opportunity is huge. In the US and EU alone, it is valued at $2.5bn in 2018. The Perfuze platform is uniquely positioned to exploit the recent, dramatic clinical shift away from medical therapy to endovascular device treatment of ischemic stroke.

This SME Instrument Phase 2 will enable company scale up and creation of 52 jobs by 2024 and will generate over €17m in turnover.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

PERFUZE LIMITED
Net EU contribution
€ 2 484 012,00
Address
UNIT 4 BUSINESS INNOVATION CENTRE NATIONAL UNIVERSITY OF IRELAND
H91H2Y0 GALWAY
Ireland
SME
Yes
Region
Ireland Northern and Western West
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 473 543,75